Nike CEO Donahoe to Retire; Hill to Return as Successor — 2nd Update
By Sabela Ojea
Nike Chief Executive John Donahoe is leaving the sneaker company.
Comapny veteran Elliott Hill is returning to Nike and will take the CEO reins as of Oct. 14. He previously served as consumer president of Nike until Donahoe took over and shuffled the sportswear company's leadership ranks about a month into the job.
Shares rose 10% to $89.10 on the news in after hours trading. The stock was down 25% year to date as of Thursday's market close.
"The board concluded it was clear Elliott's global expertise, leadership style, and deep understanding of our industry and partners, paired with his passion for sport, our brands, products, consumers, athletes, and employees, make him the right person to lead Nike's next stage of growth," Executive Chairman Mark Parker said.
Donahoe took over the top job in January 2020 after serving on the board since 2014. Under his leadership, the company saw annual sales grow significantly from about $37 billion to over $51 billion in fiscal 2024. But its stock has stumbled this year, weighed down by its decision to coast on popular shoe lines instead of innovating.
Donahoe is expected to serve as an adviser to the company for a transitional period through Jan. 31, 2025.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 19, 2024 17:12 ET (21:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks